These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. Pace E; Ferraro M; Bruno A; Chiappara G; Bousquet J; Gjomarkaj M J Asthma; 2011 May; 48(4):387-92. PubMed ID: 21391878 [TBL] [Abstract][Full Text] [Related]
3. New treatments for severe treatment-resistant asthma: targeting the right patient. Chung KF Lancet Respir Med; 2013 Oct; 1(8):639-652. PubMed ID: 24461667 [TBL] [Abstract][Full Text] [Related]
4. The use of omalizumab in asthma. Price D Prim Care Respir J; 2008 Jun; 17(2):62-72. PubMed ID: 18425299 [TBL] [Abstract][Full Text] [Related]
5. Asthma in adults. Dennis RJ; Solarte I; Rodrigo G BMJ Clin Evid; 2011 Jul; 2011():. PubMed ID: 21749735 [TBL] [Abstract][Full Text] [Related]
6. The impact of asthma exacerbations and preventive strategies. Graham LM; Eid N Curr Med Res Opin; 2015 Apr; 31(4):825-35. PubMed ID: 25530129 [TBL] [Abstract][Full Text] [Related]
7. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001 [TBL] [Abstract][Full Text] [Related]
8. Asthma pharmacotherapy. Schofield ML Otolaryngol Clin North Am; 2014 Feb; 47(1):55-64. PubMed ID: 24286679 [TBL] [Abstract][Full Text] [Related]
10. Role of long-acting beta2-adrenergic agonists in asthma management based on updated asthma guidelines. Prenner BM Curr Opin Pulm Med; 2008 Jan; 14(1):57-63. PubMed ID: 18043276 [TBL] [Abstract][Full Text] [Related]
11. Guideline for the management of chronic asthma in children--2000 update. Allergy Society of South Africa Working Group. Motala C; Kling S; Gie R; Potter PC; Manjra A; Vermeulen J; Weinberg EG; Green R S Afr Med J; 2000 May; 90(5 Pt 2):524-8, 530, 532 passim. PubMed ID: 10901828 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Hendeles L; Khan YR; Shuster JJ; Chesrown SE; Abu-Hasan M Ann Allergy Asthma Immunol; 2015 Jan; 114(1):58-62.e2. PubMed ID: 25528738 [TBL] [Abstract][Full Text] [Related]
14. Compliance therapy with anti-inflammatory antiasthmatic drugs: inhaled corticosteroids and leukotriene receptor antagonists. Riccioni G; Bucciarelli T; Mancini B; Di Ilio E; Palumbo G; D'Orazio N Clin Ter; 2007; 158(4):363-70. PubMed ID: 17953289 [TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis of omalizumab in patients with severe allergic asthma]. Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103 [TBL] [Abstract][Full Text] [Related]
16. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319 [TBL] [Abstract][Full Text] [Related]
17. Emerging therapies for severe asthma. Thomson NC; Chaudhuri R; Spears M BMC Med; 2011 Sep; 9():102. PubMed ID: 21896202 [TBL] [Abstract][Full Text] [Related]
18. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. Sorkness CA; Wildfire JJ; Calatroni A; Mitchell HE; Busse WW; O'Connor GT; Pongracic JA; Ross K; Gill MA; Kattan M; Morgan WJ; Teach SJ; Gergen PJ; Liu AH; Szefler SJ J Allergy Clin Immunol Pract; 2013 Mar; 1(2):163-71. PubMed ID: 24565455 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy of bronchial asthma. Nelson HS Allergy Asthma Proc; 2001; 22(4):217-20. PubMed ID: 11552671 [TBL] [Abstract][Full Text] [Related]
20. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]